Methanodibenzo[b,f][1,5]dioxocins as Novel Glutaminase Inhibitor with Anti-Glioblastoma Potential

Simple Summary The glutaminolysis pathway is recognized as one of the hallmarks of glioblastoma associated with tumor cell maintenance, survival, and aggressiveness. Targeting glutaminolysis emerged as a promising strategy for tumor treatments. Still, the development of glutaminase inhibitors is limited, which demands the identification of novel inhibitors for disrupting glioblastoma metabolism and its progression. Here, we report a novel library of dioxocin derivatives as glutaminase inhibitors and their pharmacological intervention for treating glioblastoma. Glutamine metabolism is an important hallmark of several cancers with demonstrated antitumor activity in glioblastoma cancer cells (GBM). GBM cells regulate glutamine and use it as a major energy source for their proliferation through the glutaminolysis process. Enzymes, such as glutaminase in glutaminolysis, can be targeted by small-molecule inhibitors, thus exhibiting promising anticancer properties. The resistance to glutaminolysis demands the development of new therapeutic molecules to overcome drug resistance. Herein, we have reported a novel library of constrained methanodibenzo[b,f][1,5]dioxocin derivatives as glutaminase (GLS) inhibitors and their anti-GBM potential. The library consisting of seven molecules was obtained through self-condensation of 2 '-hydroxyacetophenones, out of which three molecules, namely compounds 3, 5, and 6, were identified with higher binding energy values ranging between -10.2 and -9.8 kcal/mol with GLS (PDB ID; 4O7D). Pharmacological validation of these compounds also showed a higher growth inhibition effect in GBM cells than the standard drug temozolomide (TMZ). The most promising compound, 6, obeyed Lipinski's rule of five and was identified to interact with key residues Arg(307), Asp(326), Lys(328), Lys(399), and Glu(403) of GLS. This compound exhibited the best cytotoxic effect with IC50 values of 63 mu M and 83 mu M in LN229 and SNB19 cells, respectively. The potential activation of GLS by the best-constrained dibenzo[b,f][1,5]dioxocin in the tested series increased apoptosis via reactive oxygen species production in both GBM cells, and exhibited anti-migratory and anti-proliferative properties over time in both cell lines. Our results highlight the activation mechanism of a dibenzo[b,f][1,5]dioxocin from the structural basis and demonstrate that inhibition of glutaminolysis may facilitate the pharmacological intervention for GBM treatment.

Automated summary

A novel library of dioxocin derivatives was developed as glutaminase inhibitors for treating glioblastoma. These compounds exhibited significant growth inhibition effect in glioblastoma cells and showed stronger anti-tumor activity compared to the standard drug temozolomide. The most promising compound interacted with key residues of glutaminase and demonstrated potential anti-proliferative properties.